EG 427: Funding, Investors & Team (Sep 2026)
EG 427 is a French biotechnology company that is leading the way in a unique form of gene therapy known as pinpoint gene therapy.
EG 427 has raised $33.8M across 2 funding rounds on record, the most recent a Series B of $28.2M announced in Feb 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
EG 427 Company Profile and Key Stats
Latest funding round on record: Feb 2025.
EG 427 Funding Rounds
EG 427 raised $5.6M in a Series A announced in Jul 2023.
1.6 years later, a Series B of $28.2M was announced in Feb 2025.
EG 427 Founders and Leadership Team
Contact details for the EG 427 team: 2 of 2 have an email address on file.
Start 14-day free trial →EG 427 Funding Compared to Other Biotechnology Startups
EG 427's latest round of $28.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EG 427 in Biotechnology and Paris
Companies Similar to EG 427
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
EG 427 Funding FAQs
What does EG 427 do?
EG 427 is a French biotechnology company that is leading the way in a unique form of gene therapy known as pinpoint gene therapy.
How much funding has EG 427 raised?
EG 427 has raised $33.8M across 2 rounds on record. The most recent is a Series B of $28.2M announced in Feb 2025.
When did EG 427 last raise funding?
EG 427's most recent funding round on record is a Series B of $28.2M, announced in Feb 2025.
Who founded EG 427?
FundedIQ lists Alberto Epstein (Founder) at EG 427.
Who is the CEO of EG 427?
Philippe Chambon is listed as CEO at EG 427.
Where is EG 427 headquartered?
EG 427 is based in Paris, Ile-De-France, France.
How many employees does EG 427 have?
EG 427 is in the 11-50 employee band.
How does EG 427's funding compare to other Biotechnology startups?
EG 427's latest round of $28.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's EG 427 Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EG 427 is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.